A5101944299- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Eosinophilic Disorders and Syndromes
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Bone health and treatments
- Iron Metabolism and Disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Trace Elements in Health
- Hematopoietic Stem Cell Transplantation
- Gastrointestinal Tumor Research and Treatment
- CAR-T cell therapy research
South Australian Health and Medical Research Institute
2024-2025
The University of Adelaide
2015-2025
South Australia Pathology
2010-2024
Australasian Leukaemia and Lymphoma Group
2015-2024
Royal Adelaide Hospital
2024
Centre for Cancer Biology
2010-2015
University of Hong Kong
1977
Abstract Context: Imatinib is a tyrosine kinase inhibitor that has been successfully used to treat Philadelphia chromosome-positive chronic myeloid leukemia (CML) and Kit+ gastrointestinal stromal tumors. We have previously shown imatinib therapy associated with an increase in trabecular bone volume. Objective: In the present study, we performed prospective analysis of indices imatinib-treated CML patients determine mechanism responsible for this altered remodeling. Design, Patients,...